Rafferty Asset Management
DYN icon

Rafferty Asset Management’s Dyne Therapeutics DYN Stock Holding History

Rafferty Asset Management’s Portfolio DYN Stock Details DYN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$3.32M Sell
182,977
-50,858
-22% -$877K 0.01% 500
2025
Q4 		$4.57M Buy
233,835
+20,624
+10% +$391K 0.02% 448
2025
Q3 		$2.7M Buy
213,211
+102,963
+93% +$1.17M 0.01% 571
2025
Q2 		$1.05M Sell
110,248
-37,105
-25% -$409K ﹤0.01% 756
2025
Q1 		$1.54M Sell
147,353
-20,129
-12% -$288K 0.01% 645
2024
Q4 		$3.95M Buy
167,482
+2,520
+2% +$74.5K 0.01% 461
2024
Q3 		$5.93M Buy
164,962
+19,584
+13% +$779K 0.02% 384
2024
Q2 		$5.13M Sell
145,378
-199,013
-58% -$5.78M 0.02% 408
2024
Q1 		$9.78M Buy
344,391
+180,350
+110% +$4.08M 0.04% 274
2023
Q4 		$2.18M Buy
164,041
+24,632
+18% +$241K 0.01% 649
2023
Q3 		$1.25M Buy
139,409
+22,145
+19% +$239K 0.01% 733
2023
Q2 		$1.32M Buy
+117,264
New +$1.38M 0.01% 747
2023
Q1 		– Sell
-14,191
Closed -$164K – 1150
2022
Q4 		$164K Sell
14,191
-6,937
-33% -$80.3K ﹤0.01% 1091
2022
Q3 		$268K Buy
+21,128
New +$242K ﹤0.01% 1029

Other funds holding DYN

T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
AVLSA
Atlas Venture Life Science Advisors Cambridge, Massachusetts $790M AUM 223.66% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
OAG
Orbis Allan Gray Hamilton, Bermuda $23.7B AUM 65.43% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
FIS
FCPM III Services Naarden, Netherlands $722M AUM 73.61% 1-Year Est. Return

Rafferty Asset Management's DYN Position: Q1 2026 in Review

Rafferty Asset Management reduced its Dyne Therapeutics (DYN) stake by 22% in Q1 2026, selling an estimated $877K and leaving 182,977 shares worth $3.32M. The position accounts for 0.01% of the portfolio, ranked #500.

Rafferty Asset Management first reported a position in DYN in Q3 2022 and has held it in 14 quarters since. The position peaked at $9.78M in Q1 2024. 227 funds tracked by Wall St. Rank hold DYN as of Q1 2026.

  • Rafferty Asset Management held 182,977 shares of Dyne Therapeutics worth $3.32M as of Q1 2026.
  • Rafferty Asset Management sold 50,858 Dyne Therapeutics shares in Q1 2026, an estimated $877K.
  • Dyne Therapeutics made up 0.01% of Rafferty Asset Management's portfolio in Q1 2026, its #500 holding.
  • Rafferty Asset Management first reported a position in Dyne Therapeutics in Q3 2022 and has held it in 14 quarters since.
  • Rafferty Asset Management's Dyne Therapeutics position peaked at $9.78M in Q1 2024.
  • 227 funds tracked by Wall St. Rank held Dyne Therapeutics as of Q1 2026.

Based on Rafferty Asset Management's 13F filing for Q1 2026, filed 15 May 2026.